What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

December 8, 2025Blood

High-dose cryopreserved bone marrow from deceased donors may reduce relapse in HLA-mismatched allogeneic transplantation: Day 180 post-transplant HOPE update

View Full Paper

Ask AI

Bookmark

Authors

JPJeremy PantinSarah Cannon

Discussion

Member takes

Implication

Observational analysis reports 100% survival at Day 180 post-transplant in acute myeloid leukemia patients, indicating cryopreserved hematopoietic progenitor cells may improve engraftment and GVHD.

Key Points

All patients remained relapse-free at Day 180 with full donor chimerism confirmed in three patients.
Neutrophil engraftment occurred as early as 15 days post-transplant, demonstrating efficacy of the cryopreserved bone marrow.
Transplants utilized 4/8 and 6/8 HLA-matched cells, showing feasibility and safety in HLA-mismatched conditions.
Findings highlight the potential impact of high-dose cryopreserved CD34+ cells in addressing relapse prevention and GVHD management.

Cite This Study

Jeremy Pantin (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db3a https://doi.org/10.1182/blood-2025-5976

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis reports 100% survival at Day 180 post-transplant in acute myeloid leukemia patients, indicating cryopreserved hematopoietic progenitor cells may improve engraftment and GVHD.

High-dose cryopreserved bone marrow from deceased donors may reduce relapse in HLA-mismatched allogeneic transplantation: Day 180 post-transplant HOPE update

Discussion

Member takes

Implication

Key Points

Cite This Study

High-dose cryopreserved bone marrow from deceased donors may reduce relapse in HLA-mismatched allogeneic transplantation: Day 180 post-transplant HOPE update

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider